KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Capital Expenditures (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Capital Expenditures data on record, last reported at $21.8 million in Q4 2025.

  • For Q4 2025, Capital Expenditures rose 43.67% year-over-year to $21.8 million; the TTM value through Dec 2025 reached $70.1 million, up 34.93%, while the annual FY2025 figure was $70.1 million, 34.93% up from the prior year.
  • Capital Expenditures reached $21.8 million in Q4 2025 per AMRX's latest filing, up from $12.3 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $22.8 million in Q2 2025 and bottomed at $5.0 million in Q2 2022.
  • Average Capital Expenditures over 5 years is $13.0 million, with a median of $11.7 million recorded in 2021.
  • Peak YoY movement for Capital Expenditures: tumbled 40.75% in 2021, then surged 137.73% in 2023.
  • A 5-year view of Capital Expenditures shows it stood at $17.5 million in 2021, then crashed by 34.47% to $11.5 million in 2022, then decreased by 13.96% to $9.9 million in 2023, then skyrocketed by 53.62% to $15.2 million in 2024, then surged by 43.67% to $21.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $21.8 million in Q4 2025, $12.3 million in Q3 2025, and $22.8 million in Q2 2025.